Pharmacologically targeting the JAK-STAT pathway overcomes resistance to chidamide in NKTL
NKTL
We hypothesized that targeting the JAK-STAT pathway could reverse chidamide resistance in NKTL cell lines. To test this hypothesis, we treated the chidamide-resistant NKTL cell lines (HANK1 and SNK6) with tofacitinib (JAK inhibitor), chidamide or a combination of both drugs for 96 h and determined the combination index (Fig. JAK-STAT inhibitors overcome chidamide resistance in NKTL cells. 